Pearl Therapeutics, Inc.
http://www.pearltherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pearl Therapeutics, Inc.
Big Pharmas Trust To The Science In Zantac Lawsuits
Billions of dollars have been wiped off the value of big pharma stocks as the market finally woke up to widescale litigation concerning allegations of increased cancer risk associated with the use of ranitidine. Two companies, GSK and Sanofi, are confident that there is no link.
US OTC Switch For Cialis At Top Of To-Do List For Sanofi’s North American Consumer Health Chief
Andrew Loucks moves to Sanofi from helm of consumer health and technology firm Sensory Cloud as business navigates gaining US OTC heartburn market share for Zantac brand, which it relaunched with famotidine replacing ranitidine as the active ingredient.
Bayer Suggests Self-Care Industry Follow Five Principles As 'Blueprint' For Product Development
Bayer proposes five science-based principles to guide industry’s self-care research and development to reframe self-care and earn consumer trust.
Stock Watch: Debt And Biotech Do Not Mix
Even with higher interest rates, some debt on the balance sheets of profitable biotechs is healthy. However, among loss-making biotechs and in the current environment, raising new debt has unhealthy connotations.